
    
      The DESSOLVE II clinical trial is to assess the safety and performance of the
      sirolimus-eluting MiStent as compared to the Endeavor DES for the treatment for improving
      coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete
      de novo lesions in the native coronary arteries.
    
  